A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

Multiple Sclerosis Clinical Trial

Official title:

A Phase 1, Dose-Escalating, Open-label Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Single Dose of IV IMS001 in Subjects With Multiple Sclerosis and Treatment Failure to Prior Disease Modifying Treatments (DMTs)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04956744
• Other study ID #: IMS001-01
• Status: Recruiting
• Phase: Phase 1
• Start date: August 31, 2021
• Est. completion date: December 2027

Study information

• Verified date: September 2023
• Source: ImStem Biotechnology
• Contact: Richard Kim, MD
• Phone: 860-281-7836
• Email: richard.kim[@]imstem.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments. IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC). MSCs have the potential to modulate disease course.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 2027
• Est. primary completion date: December 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Provides signed and dated informed consent in accordance with local regulations.

• 18 to 65 years of age.

• Diagnosis of MS.

• Has had an inadequate response DMTs.

• EDSS within protocol parameters.

• Able and willing to undergo MRIs.

• Must be clinically stable for 1 month prior to Day 1.

Exclusion Criteria:

• Has a known or suspected hypersensitivity to human serum albumin, diphenhydramine, acetaminophen, methylprednisolone, or any of the components of IMS001.

• Has history of excluded medications, per protocol, prior to Day 1.

• Has a history of neoplastic disease except for basal cell carcinoma, non-metastatic squamous cell carcinoma of the skin that has been excised with clean margins, or adequately treated in-situ carcinoma of the cervix.

• Prior history of any other autoimmune disease, myelodysplasia, or hematologic disease.

• Prior treatment with any allogeneic cell therapy or tissue transplant.

• Prior history of smoking equivalent to ?20 cumulative pack years of cigarettes.

• Recent clinically significant infection during the Screening Phase.

• Has any medical or psychiatric condition that would impact outcome or participation in the study.

• Has clinically significant abnormal findings on the electrocardiogram (ECG) during the Screening Phase.

• Has known or documented human immunodeficiency virus (HIV) infection or active Hepatitis B, or C.

• Has an elevated liver function test abnormality during the Screening Phase.

• Has abnormalities of blood count during the Screening Phase.

• Has laboratory abnormalities of renal function during the Screening Phase.

• Has other clinically significant laboratory abnormalities during Screening Phase.

• Body weight =120 kg.

• Women pregnant, breast feeding, or planning to become pregnant during the study.

• Is unavailable for the duration of the trial, is likely to be noncompliant with the protocol, or is generally felt to be unsuitable by the principal investigator.

• Current or recent participation in any other clinical or device trials within 3 months prior to Day 1.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Biological:
• IMS001
IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC).

Locations

Country	Name	City	State
United States	Shepherd Center	Atlanta	Georgia
United States	Rocky Mountain MS Clinic	Salt Lake City	Utah
United States	UMass Memorial Medical Center	Worcester	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
ImStem Biotechnology	Rho, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability	Frequency of treatment-emergent adverse events (TEAEs).	Day 1 to Month 60
Primary	Safety and tolerability	Clinically significant laboratory abnormalities.	Day 1 to Month 60

External Links

•   Imstem Biotechnology